Genetic Testing for Pulmonary Arterial Hypertension
Genes Associated With Development of Pulmonary Arterial Hypertension in Patients With Congenital Shunt Lesions
Recruiting
N/A
Interventional Study
Heart Defects, Congenital
Pulmonary Arterial Hypertension
Genetic Testing
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Interventional
- Purpose
- Diagnostic
- Participants needed
- 21 (estimated)
- Sponsor
- Universitaire Ziekenhuizen KU Leuven · Other
Who this trial is looking for
This trial is looking for people with specific heart defects and pulmonary arterial hypertension (PAH). Participants will be tested for genetic factors that may influence their condition.
Are You a Good Fit for This Trial?
You may be able to join if
- I have been diagnosed with atrial septal defect (ASD) or ventricular septal defect (VSD).
- I have developed pulmonary arterial hypertension (PAH).
- I have family members affected by ASD or VSD.
You may not be able to join if
- I have other congenital heart disease.
- I have a history of mental retardation.
- I have dysmorphic characteristics.
- I have chronic lung disease or reduced lung capacity.
- I have had a pulmonary embolism.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Pulmonary arterial hypertension (PAH) in patients with congenital heart disease (CHD) is associated with considerable morbidity and even mortality.
Next to environmental risk factors, the investigators believe that there is an important role of genetic predisposition to develop PAH in CHD. There often is a discrepancy between the severity of PAH and the CHD, where it is useful to screen for PAH g…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Previous diagnosis of secundum atrial septal defect (ASD) or ventricular septal defect (VSD), with or without repair
* Development of PAH, defined as mean PAP ≥ 25 mmHg by right heart catheterization, in combination with a pulmonary wedge pressure of ≤ 15 mmHg and a PVR (pulmo…
Contacts